

FDA-Novo Nordisk Teleconference

Date of Teleconference: December 17, 2018, 1:30 – 2:00 PM ET

Application STN: BLA 125671/0

Applicant: Novo Nordisk, Inc.

FDA Attendees:

Najat Bouchkouj, MD, CBER/OTAT/DCEPT

Lin Huo, PhD, CBER/OBE/DB

Jean Dehdashti, MS, RAC, CBER/OTAT/DRPM

Novo Nordisk, Inc., Attendees:

Stephanie Seremetis, Corp. Vice President, Hemophilia

Wan Hui Ong Clausen, Principal Statistician, Biostatistics Biopharm

Jesper Nellemann, Project Vice President, Biopharm Management

Frank Bringstrup, Senior Global RA Lead, Biopharm

Michelle Thompson, Senior Director RA, Clinical Medical and Regulatory (CMR)

Hiral Palkhiwala, Specialist RA, CMR

Barbara Davies, Senior Manager, CMR

Agenda: Novo Nordisk requested a teleconference to discuss the points listed below regarding the two recent FDA Stats/Clinical information requests (IRs) issued, dated December 13 and December 16, 2018:

- The analyses requested were not a topic at the Late Cycle Meeting (LCM); i.e., the outcome assessments seem to have changed in the recent past
- We will provide everything the FDA requests, but are not able to provide everything within the specified target response dates
- We need clarification on the tables/assessment of hemostatic response, as this endpoint is calculated based on the time of product administration; thus there is no hemostatic response data for non-treated bleeds

Meeting Summary:

Regarding Novo Nordisk's discussion point one and the Late Cycle Meeting, FDA stated that the review of BLA 125671/0 is ongoing, and Novo Nordisk can expect that IRs will be issued accordingly throughout the review cycle.

FDA clarified that they are trying to gain an understanding of the non-treatment required bleeds with the two IRs, dated December 13 and December 16, 2018, and how the annualized bleed rates (ABRs) would be affected with the inclusion or exclusion of the non-treated bleeds. Novo Nordisk stated that they fully intend to provide a complete response to FDA issued IRs; however, requested clarification on the tables/assessment of hemostatic response, as this endpoint is calculated based on the time of product administration, therefore there would be no hemostatic response data for non-treated bleeds. FDA clarified that they agree with Novo Nordisk assessment, and that Novo

Nordisk would no longer need to provide revised analysis of these tables. FDA stated that they would provide a revised list of tables with response due date to Novo Nordisk following the meeting.

Novo Nordisk stated that they anticipated a delay in providing the analysis datasets and programs for the tables requested by FDA, as the current datasets are not in CDISC format, and will need to be migrated from Legacy format. FDA requested that this information be provided as soon as possible, and if possible, by January 3, 2019. Novo Nordisk stated that they would try to provide the information by the requested date; however, they anticipated a delayed response.

Lastly, Novo Nordisk agreed to provide the output tables and details of subjects with joints non-treated bleeds as requested by 12/20/2018. They will also inform FDA about their timeline of when they will send the programs and analysis datasets for the 5 datasets in the following order:

1. High priority (preferably by 1/3/2019):
 - a. 3859 Main
 - b. 3885 Peds Main
 - c. 3859 Main Ext1
2. Lower priority (by 1/7 or 1/10/2019):
 - a. 3859 Main Ext2
 - b. 3885 Peds Ext